Aurobindo Pharma shares climbed 2.5 percent in morning on Monday on receiving approval from the US health regulator for anaesthesia drug.
The drug maker has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Vecuronium Bromide Injection, 10mg and 20mg.
Vecuronium Bromide is a generic equivalent of Organon's Norcuron injection. "The product will be launched in Q4FY19," Aurobindo said.
The drug is used as part of general anaesthesia to provide skeletal muscle relaxation during surgery or mechanical ventilation. It is also used to facilitate endotracheal intubation.
The approved product has an estimated market size of $11 million for the twelve months ending September 2018, according to IQVIA.
Aurobindo said this is the 58th ANDA to be approved out of Unit IV formulation facility in Hyderabad facility which is used for manufacturing general injectable & ophthalmic products.
The company now has a total of 397 ANDA approvals (369 final approvals including 20 from Aurolife Pharma LLC and 28 tentative approvals) from USFDA.
We provide you sure shot Commodity & Equity Market Tips, Intraday tips, share market tips, Mcx bullion tips, Mcx tips, Crude tips, Stock tips, Future and Cash tips with Technical & Fundamental Research.
Visit: www.ripplesadvisory.com
Contact us @ +91-9644405056
Source: Moneycontrol
No comments:
Post a Comment